Daclatasvir bulk supplier for pharma manufacturers

Daclatasvir 30 mg, 60 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 30 mg, 60 mg

Reference Brands: Daklinza® (US & EU)

Category: Hepatitis

Daclatasvir is an effective oral antiviral used to treat chronic Hepatitis C infection by inhibiting the NS5A protein critical for viral replication. Available as 30 mg and 60 mg tablets, it is manufactured under EU-GMP and USFDA standards. Widely used in combination therapies, Daclatasvir supports broad HCV genotype coverage. Ideal for B2B supply, hospital tenders, and licensing, it comes with comprehensive regulatory dossiers enabling quick registration in global markets.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Daclatasvir? List it or send an offer →

Product Description: Daclatasvir is a potent direct-acting antiviral (DAA) used in the treatment of chronic Hepatitis C virus (HCV) infection. It functions by selectively inhibiting the NS5A protein, a key factor in viral replication and assembly. Available as oral tablets in strengths of 30 mg and 60 mg, Daclatasvir is commonly used in combination with Sofosbuvir or other antivirals for broad genotype coverage. Manufactured under strict EU-GMP and USFDA standards, it is suitable for B2B supply, hospital tenders, and licensing. Comprehensive regulatory dossiers support fast market registration and global distribution.

Daclatasvir — third party manufacturing & bulk supply

Daclatasvir 30 mg, 60 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Daclatasvir is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Daclatasvir listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Daclatasvir →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Daclatasvir is listed as Tablet in 30 mg, 60 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Daclatasvir is referenced against Daklinza® (US & EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.